跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,188 条关于
“KEYNOTE-667”
全部
1,188
临床试验
507
药物
300
机构
6
资讯
375
去年
CAR T-Cell Therapy Shows Improved Survival in Transformed Follicular Lymphoma
去年
Pembrolizumab Shows Promise in Younger Patients with Low-Risk Hodgkin Lymphoma
去年
Merck Highlights Hematology Pipeline at ASH 2024 with Zilovertamab Vedotin and Nemtabrutinib Data
2年前
Merck Discontinues Phase 3 Trials of Pembrolizumab in NSCLC and CSCC
2年前
KEYNOTE-789: Pembrolizumab Plus Chemotherapy Fails to Improve Survival in EGFR-Mutated NSCLC
去年
Pembrolizumab Plus Chemotherapy Improves Overall Survival in HER2-Positive Gastric Cancer
2年前
Pembrolizumab Demonstrates Sustained Survival Benefits in Advanced Melanoma After 10-Year Follow-Up
2年前
Pembrolizumab Improves Overall Survival in Clear Cell Renal Cell Carcinoma
3个月前
The Evolving Role of Biotechnology Keynote Speakers in Shaping Pharmaceutical R&D Strategy
2年前
Pembrolizumab Shows Sustained Survival Benefit in Advanced Melanoma After 10-Year Follow-up
第 1 页,共 38 页
上一页
下一页